- Home
- TCRX vs ELUT Comparison
TCRX vs ELUT Comparison
Compare TCRX & ELUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCRX
- ELUT
- Stock Information
- Founded
- TCRX 2018
- ELUT 2015
- Country
- TCRX United States
- ELUT United States
- Employees
- TCRX N/A
- ELUT N/A
- Industry
- TCRX Biotechnology: Pharmaceutical Preparations
- ELUT Medical Specialities
- Sector
- TCRX Health Care
- ELUT Health Care
- Exchange
- TCRX Nasdaq
- ELUT Nasdaq
- Market Cap
- TCRX 82.1M
- ELUT 71.5M
- IPO Year
- TCRX 2021
- ELUT 2020
- Fundamental
- Price
- TCRX $1.45
- ELUT $2.11
- Analyst Decision
- TCRX Strong Buy
- ELUT Strong Buy
- Analyst Count
- TCRX 6
- ELUT 2
- Target Price
- TCRX $9.50
- ELUT $8.00
- AVG Volume (30 Days)
- TCRX 669.3K
- ELUT 27.0K
- Earning Date
- TCRX 08-11-2025
- ELUT 08-06-2025
- Dividend Yield
- TCRX N/A
- ELUT N/A
- EPS Growth
- TCRX N/A
- ELUT N/A
- EPS
- TCRX N/A
- ELUT N/A
- Revenue
- TCRX $4,421,000.00
- ELUT $23,711,000.00
- Revenue This Year
- TCRX $159.20
- ELUT $20.10
- Revenue Next Year
- TCRX N/A
- ELUT $85.89
- P/E Ratio
- TCRX N/A
- ELUT N/A
- Revenue Growth
- TCRX N/A
- ELUT N/A
- 52 Week Low
- TCRX $1.02
- ELUT $1.61
- 52 Week High
- TCRX $7.89
- ELUT $5.24
- Technical
- Relative Strength Index (RSI)
- TCRX 46.44
- ELUT 49.75
- Support Level
- TCRX $1.39
- ELUT $1.70
- Resistance Level
- TCRX $1.73
- ELUT $1.99
- Average True Range (ATR)
- TCRX 0.15
- ELUT 0.14
- MACD
- TCRX -0.02
- ELUT 0.01
- Stochastic Oscillator
- TCRX 12.53
- ELUT 38.17
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
About ELUT Elutia Inc.
Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.